Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy

Li, Qing; Su, Rui; Bao, Xiaoyi; Cao, Kunxia; Du, Yangyang; Wang, Nanya; Wang, Jianfeng; Xing, Fan; Yan, Fei; Huang, Keke; Feng, Shouhua

doi:10.1016/j.actbio.2022.03.030

Cited by 54 publications

(27 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathological assay was performed as previously described . Briefly, the paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) according to standard protocols.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Liu

Song

Wang

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Cancer immunotherapy has achieved considerable clinical progress in recent years on account of its potential to treat metastatic tumors and inhibit recurrence. However, low patient response rates and dose-limiting toxicity are the major limitations of immunotherapy. Nanoparticle-based photothermal immunotherapy can amplify antitumor immune responses, although poor tumor penetration depth of near-infrared radiation (NIR) and the immunosuppressive tumor microenvironment significantly dampen its effects. We designed a nanoplatform based on gold nanorods for NIR-II-mediated photothermal therapy (PTT) combined with N 6methyladenosine (m 6 A) demethylase inhibition to achieve enhanced photothermal immunotherapy against prostate cancer. The GNRs were assembled layer by layer with polystyrenesulfonate as the interconnecting layer and then coated with a cationic polymer of γ-cyclodextrin (CD)-cross-linked low-molecular-weight polyethylenimine that was conjugated to an 8-mer peptide targeting the prostate tumor-specific gastrin-releasing peptide receptor. The m 6 A RNA demethylase inhibitor meclofenamic acid (MA) was then loaded into the CD cavity through hydrophobic interactions. GNR-CDP8MA specifically targeted the prostate tumor cells and selectively accumulated at the tumor site in vivo. In addition, GNR-CDP8MA almost completely ablated prostate cancer cell-derived tumors upon 1208 nm laser irradiation. Mechanistically, NIR-II triggered the release of MA from GNR-CDP8MA, which increased global mRNA m 6 A methylation and decreased the stability of PDL1 transcripts. Furthermore, GNR-CDP8MA-mediated PTT-induced immunogenic cell death in the primary tumor and consequently enhanced antitumor immunity by activating the antigen-presenting dendritic cells and tumorspecific effector T cells in the metastatic tumors. This study offers insights into synergistic m 6 A RNA methylation and PTT as an effective strategy for cancer immunotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Histopathological assay was performed as previously described. 34 Briefly, the paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E) according to standard protocols. For immunohistochemistry (IHC), the sections were stained with anti-PCNA antibody(Cell Signaling Technology, 13110S).…”

Section: ■ Experimental Sectionmentioning

confidence: 99%

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Liu

Song

Wang

et al. 2022

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to iron metabolism and lipid peroxidation responses, a wide range of intracellular antioxidant mechanisms also plays an important role in regulating ferroptosis sensitivity ( 63 , 64 ). Glutathione (GSH), the most important intracellular antioxidant metabolite, requires cysteine as a raw material for its synthesis, and cells can endogenously synthesize cysteine via the transsulfuration pathway to resist ferroptosis ( 65 , 66 ). In addition, myristoylation modification of ferroptosis inhibitory protein 1 leads to a nicotinamide adenine dinucleotide (NADH)–dependent decrease in coenzyme Q, which acts as a radical-trapping antioxidant to inhibit lipid peroxide proliferation ( 67 , 68 ).…”

Section: Ferroptosismentioning

confidence: 99%

Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer

Zhang

Liu

2022

Front. Immunol.

View full text Add to dashboard Cite

Ovarian cancer (OC) is one of the most common malignancies that causes death in women and is a heterogeneous disease with complex molecular and genetic changes. Because of the relatively high recurrence rate of OC, it is crucial to understand the associated mechanisms of drug resistance and to discover potential target for rational targeted therapy. Cell death is a genetically determined process. Active and orderly cell death is prevalent during the development of living organisms and plays a critical role in regulating life homeostasis. Ferroptosis, a novel type of cell death discovered in recent years, is distinct from apoptosis and necrosis and is mainly caused by the imbalance between the production and degradation of intracellular lipid reactive oxygen species triggered by increased iron content. Necroptosis is a regulated non-cysteine protease–dependent programmed cell necrosis, morphologically exhibiting the same features as necrosis and occurring via a unique mechanism of programmed cell death different from the apoptotic signaling pathway. Pyroptosis is a form of programmed cell death that is characterized by the formation of membrane pores and subsequent cell lysis as well as release of pro-inflammatory cell contents mediated by the abscisin family. Studies have shown that ferroptosis, necroptosis, and pyroptosis are involved in the development and progression of a variety of diseases, including tumors. In this review, we summarized the recent advances in ferroptosis, necroptosis, and pyroptosis in the occurrence, development, and therapeutic potential of OC.

show abstract

“…GCMNPs downregulated glutathione‐dependent peroxidases 4 and induced ferroptosis in AML and CRC cells, thereby increasing lipid peroxidation levels. In vivo studies showed that GCMNPs synergized with ferumoxytol and anti‐PD‐L1 and synergistically improved the T‐cell immune response against leukemia and colorectal tumors 231 …”

Section: Mode Of Administration or Different Therapies For Cancer Tre...mentioning

confidence: 99%

“…In vivo studies showed that GCMNPs synergized with ferumoxytol and anti-PD-L1 and synergistically improved the Tcell immune response against leukemia and colorectal tumors. 231 In brief, a new design of vehicles for drug carriers is discussed for sustained release to achieve better disease control, especially for cancer treatment. Different types of nanocarriers are described based on inorganic and organic moieties with various shapes and sizes.…”

Section: Immune Therapymentioning

confidence: 99%

Nanomedicine and versatile therapies for cancer treatment

Shukla

Maiti

2022

MedComm

View full text Add to dashboard Cite

The higher prevalence of cancer is related to high rates of mortality and morbidity worldwide. By virtue of the properties of matter at the nanoscale, nanomedicine is proven to be a powerful tool to develop innovative drug carriers with greater efficacies and fewer side effects than conventional therapies. In this review, different nanocarriers for controlled drug release and their routes of administration have been discussed in detail, especially for cancer treatment. Special emphasis has been given on the design of drug delivery vehicles for sustained release and specific application methods for targeted delivery to the affected areas. Different polymeric vehicles designed for the delivery of chemotherapeutics have been discussed, including graft copolymers, liposomes, hydrogels, dendrimers, micelles, and nanoparticles. Furthermore, the effect of dimensional properties on chemotherapy is vividly described. Another integral section of the review focuses on the modes of administration of nanomedicines and emerging therapies, such as photothermal, photodynamic, immunotherapy, chemodynamic, and gas therapy, for cancer treatment. The properties, therapeutic value, advantages, and limitations of these nanomedicines are highlighted, with a focus on their increased performance versus conventional molecular anticancer therapies.

show abstract

Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy

Cited by 54 publications

References 57 publications

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer

Nanomedicine and versatile therapies for cancer treatment

Contact Info

Product

Resources

About

Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy

Cited by 54 publications

References 57 publications

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N6-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N6-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer

Nanomedicine and versatile therapies for cancer treatment

Contact Info

Product

Resources

About

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy

Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving N⁶-Methyladenosine-Mediated Second Near-Infrared Photothermal Immunotherapy